|Home | About | Journals | Submit | Contact Us | Français|
Cells, scaffolds, and growth factors play important roles in bone regeneration. Bone morphogenetic protein 9 (BMP9), a member of BMP family, could facilitate osteogenesis by regulating growth factors and promoting angiogenesis. Similar to other stem cells, rat dental follicle stem cells (rDFCs), the precursor cells of cementoblasts, osteoblasts and periodontal ligament cells, can self-renew and exhibit multipotential capacity. Coralline hydroxyapatite (CHA) has good biocompatibility and conductivity required for bone tissue engineering. Here, we reported that BMP9 could enhance the osteogenic differentiation of rDFCs in cell culture. Moreover, our results suggested that BMP9 acted through the Smad1/5/8 signaling pathway. We also produced a novel scaffold that encompasses bio-degradable CHA seeded with recombinant adenoviruses expressing BMP9-transfected rDFCs (Ad-BMP9-transfected rDFCs). With this implant, we achieved more alveolar bone regeneration in the alveolar bone defect compared to blank group, CHA group and rDFCs group. Our results provided a novel bio-implants composed of Ad-BMP9-transfected rDFCs and CHA scaffolds and its mechanism is regarding the activation of Smad1/5/8 signaling pathway in BMP9-induced rDFCs osteogenesis.
Periodontitis is one of the most common oral diseases1. It has been characterized as a chronic infectious and inflammatory disease, which affects periodontal tissues and eventually leads to tooth loss2. The ultimate goal of all periodontal treatment is to reconstruct the periodontal tissue and restore its functions3. However, the current conventional methods (i.e. supra-and sub-gingival scaling, root planning, and surgical treatment) could treat periodontitis but have shown limited effectiveness in regenerating periodontal tissues regeneration4–6. Recently, tissue engineering techniques have made enormous progress in the field of bone regeneration through utilizing a combination of three-dimensional (3D) scaffolds, cells and growth factors7–9.
In 2008, Yao et al. proved that dental follicle stem cells (DFCs), derived from dental follicle, could contribute to the development of periodontal tissue10. Similar to other stem cells, the DFCs display both self-renewal and multipotential differentiation capacity11. It was reported that DFCs could express the markers of mesenchymal stem cells (MSCs) including Nestin, notch-1 and Stro-112, 13. Further studies have shown that DFCs could differentiate into osteoblasts, cementoblasts, neuroblasts, fibroblasts and lipoblasts11, 14, 15.
Compared to other family members, BMP9 had more potent in inducing osteogenic differentiation of stem cells16–19. Xu20 confirmed that BMP9 induced osteogenic differentiation in mesenchymal stem cell line C3H10T1/2. Randall21 showed that BMP9 could induce large volumes of ectopic bone formation adjacent to spine in vivo. The question still remains on whether BMP9 could promote periodontal alveolar bone regeneration. Our previous study demonstrated that BMP9 could stimulate the expression of osteogenic differentiation genes in rDFCs. However, further animal studies are intensely necessary to further characterize the osteogenetic potential of BMP9-induced cells in vivo. In previous researches, Wei Shui22 reported that the application of BMP9-transduced C2C12 cells and type I collagen sponge or HA-TCP scaffold achieved robust and mature cancellous bone formation. Jing Wang23 indicated that the mineralization and maturity of BMP9-induced ectopic bone formation could be enhanced by Nell1 expression. Ye24 found that thermoresponsive polydiolcitrate-gelatin scaffold facilitated BMP9-induced osteogenic differentiation of MSCs in vivo and could promote the formation of well-ossified and vascularized trabecular bone-like structures in a mouse model of ectopic bone formation. Viral vectors for gene delivery are the most popular vectors used in research due to their high efficiency17. Delivery of the gene by adenoviral vectors can be better controlled and more efficient than delivery of the protein17. Recombinant human bone morphogenetic protein 9 (rhBMP9) exhibited significantly weaker osteogenic activity, compared with that induced by recombinant adenoviruses expressing BMP9 (Ad-BMP9)19. For these reasons, we considered investigating the possibility of seeding BMP9-induced rDFCs on scaffolds to repair periodontal alveolar bone defect in vivo.
Members of the BMP family could induce osteogenic differentiation of MSCs through Smad-dependent25, 26 or Smad-independent signaling pathway27, 28. Researchers have demonstrated Smad-dependent signal pathway begins with binding the BMP type I receptors to the BMP type II receptors, then the activated complex receptors promotes the phosphorylation of Smad1/5/8. The phosphorylated Smad1/5/8 forms a complex with Smad4 in the nucleus, which activates the transcription of target osteogenic genes29. And, we have demonstrated that BMP9 could effectively promote the osteogenic differentiation of rDFCs by regulating P38 and ERK1/2 MAPK manner, a Smad-independent signaling pathway11. However, it still remains unclear whether BMP9 could induce the osteogenic differentiation in rDFCs by activating the Smad-dependent signaling pathway directly or indirectly.
Coralline hydroxyapatite (CHA) scaffolds which have good biocompatibility and conductivity, have been widely applied in tissue engineering30–32. CHA scaffolds applied in clinical studies are manufactured by the hydrothermic conversion of hydroxyapatite to calcium carbonate exoskeletons of sea coral30–32. In recent studies, CHA scaffolds were used as porous materials to promote bone regeneration33. Interestingly, it was shown that human MSCs could adhere to the surfaces of CHA, then proliferate and differentiate34. For this reason, we considered investigating the possibility of seeding rDFCs on CHA scaffolds.
To date, there is no study that investigates the role of rDFCs transfected with Ad-BMP9 and co-cultured with CHA in periodontal alveolar bone regeneration and the osteogenic mechanism of BMP9-induced rDFCs. In this study, we transfected rDFCs with Ad-BMP9 then culture those cells on CHA scaffolds. The aims of this study were as follows: (i) to assess whether Ad-BMP9 or CHA can induce osteogenesis in rDFCs, (ii) to determine whether the combination of Ad-BMP9-transfected rDFCs and CHA scaffolds can effectively promote alveolar bone formation in vivo and (iii) to identify whether Smad1/5/8 signaling pathway is involved in the process of BMP9-induced osteogenesis in rDFCs.
As shown in Fig. 1a–c, the primary rDFCs were polygonal and fusiform. After the third passage, rDFCs appeared fibroblast-like fusiform (Fig. 1d). 1 to 3 cell nucleoli and highly-densed granules can be observed in the cytoplasm (Fig. 1d). Green fluorescence could be detected in rDFCs 24hours after adenovirus expressing bone morphogenetic protein 9 (Ad-BMP9) or adenovirus green fluorescence (Ad-GFP) transfection. After 48hours in culture, the expression of fluorescence increased and the transfection efficiency was about 70%-80% without changing in cells shape (Fig. 1e and f). The green fluorescence was regarded as a mark of Ad-BMP9-transfected rDFCs successfully.
To assess the osteogenic effect of BMP9, we performed alkaline phosphatase staining (ALP staining) experiments in the cultured rDFCs. The elevated ALP activity could be distinguished from day 5 in BMP9 group and reached the peak level at day 7 (Fig. 2A,B). We further quantified the mRNA level of alkaline phosphatase (ALP), an important early osteogenic marker11, 35, by means of Real Time-qPCR. As expected, the expression showed the similar pattern with the maximal expression on day 7 (Fig. 2B). Osterix, one of the main osteogenic determinants36, remained at a high level on day 3 and gradually decreased from day 3 to day 9. The expression of osteopontin (OPN), the late osteogenesis marker11, 35, 37, continued to increase from the third day and reached the maximal level on day 9. Alizarin red staining was performed to detect the calcium deposition. Alizarin Red staining showed some large and red calcified nodules in BMP9 group on day 14. In blank and GFP groups, the calcified nodules were occasionally found and lightly stained (Fig. 2C). The results suggested that BMP9 could promote the osteogenesis of rDFCs.
The surface structure of CHA scaffolds was illustrated by scanning electron micrographs (SEM). The results revealed that CHA scaffolds had lots of pores with a diameter ranging from 100 to 600μm (Fig. 3A). Furthermore, SEM also showed that the cells adhered to the surface and side wall of visual pores of CHA scaffolds (Fig. 3A). First sign of adhesion of rDFCs to the CHA scaffolds appeared after 24hours in co-culture (Fig. 3A,b,c and d). All the cells showed sufficient adhesion with polygonal and fusiform shape. Moreover, pseudopodium of cells could be observed (Fig. 3A,c and d).The number of cells on the surface and the side walls of visual pores gradually increased over time. The accumulation of cells and secretory extracellular matrix began to contact with each other and adhered to the surface of CHA on day 4 (Fig. 3A,e and f). Extracellular matrix fully covered the surface of CHA scaffolds on day 7 (Fig. 3A,g and h).
To assess the effect of CHA on promoting osteogenic differentiation potential of rDFCs, we distributed into 3 groups by culture them in normal growth medium (rDFCs group), osteogenic differentiation medium (osteogenic induction group), or co-culture with CHA scaffolds in normal growth medium (CHA group). After 3, 5, 7 days, we extracted the cells from culture for gene expression study (Fig. 3B,C and D). The expression of ALP, a well-established early osteogenic marker11, 35, elevated dramatically in CHA group compared to the control group on day 5 and 7 (P<0.01). But, it was still not comparable to the ALP expression level in the osteogenic induction group (P<0.1). Cells cultured with CHA scaffolds exhibited higher level expression of late osteogenic gene, OPN11, 35, 37, compared with those cells without any treatment (rDFCs group) on day 7 and 9 (P<0.001), though lower level than cells stimulated by osteogenic differentiation medium (osteogenic induction group)on day 5, 7 and 9 (P<0.01) (Fig. 3C). The expression levels of Osterix, one of the main osteogenic determinants36 were significantly higher in CHA group than those in the rDFCs group on day 5, 7 and 9 (P<0.01), and lower than those in osteogenic induction group on day 5, 7 and 9 (P<0.01) (Fig. 3D). These results suggest that CHA scaffolds enhance the osteogenic differentiation of rDFCs, but it is not as effective as the osteogenic induction medium.
In order to evaluate the osteogenic potential of BMP9-treated rDFCs in vivo, we prepared CHA, rDCFs/CHA, GFP-rDCFs/CHA, and BMP9-rDCFs/CHA implants for animal experiments. First, we chose to use an ectopic bone formation animal model, as this model would allow us to test whether the novel compound of Ad-BMP9-transfected rDFCs-CHA could supports bone formation in such an environment without any stimulation. And we performed ectopic implantation under the skin of immunodeficient mice. After 6 weeks, the implants were removed and decalcified. Paraffin sections were collected and stained with hematoxylin and eosin for observation. However, there is no evidence of mature new bone formation observed around the CHA scaffolds in all the four groups (Fig. 4A). Interestingly, we found fibrous tissues and immature fibrous-like bone with macrophagocytes and plenty of blood vessels in rDFCs/CHA group and BMP9-rDFCs/CHA group. And there were only fibrous tissues in CHA group. The alveolar bone defect was treated with or without those implants in a rat model in order to test whether the compound implantation would support bone formation to restore alveolar bone defect in an acute traumatic inflammatory environment. After 6 weeks, HE staining was done. A little bone formation was observed in blank and CHA group. The defect filled with fibrous connective tissues showed only a little new alveolar bone along the edge of host bone in blank group (Fig. 4B,e). In CHA group, defects filled with CHA showed a little bone formation with fibrous connective tissue around scaffolds (Fig. 4B,f). Meanwhile, amount of new bone formation and irregularly arranged fibrous connective tissues were also found in rDFCs/CHA treated animals (Fig. 4B,h). Surprisingly, there were numerous new bone formations surrounding the CHA scaffolds and plenty of blood vessels in the defect area with BMP9-rDFCs/CHA implants as showed (Fig. 4B,i). The findings were accordance with the result of image analysis of new bone percentage (Fig. 4E). There were significant differences between BMP9-rDFCs/CHA group and all the other groups (P<0.01). There was more new bone in rDFCs/CHA group than that in CHA group (P<0.01) and blank group (P<0.01). And the result showed less new bone in blank group compared to CHA group (P<0.05). Taken together, the novel compound implant (BMP9-rDFCs/CHA) achieved the best effects in the restoration of alveolar bone defect.
The 3D reconstruction image from Micro CT data was also used to analyze the new bone formation in each group. A bone defect was still visible in blank group. Meanwhile, the defects treated with CHA, rDFCs/CHA or BMP9-rDFCs/CHA implants were filled with newly generated bones and CHA scaffolds. The results: bone volume (BV) and bone ratio (volume of new formation bone /volume of interest, BV/TV) also confirmed that there were more volume of new bones in the BMP9-rDFCs/CHA implant group compared to rDFCs/CHA group (P<0.01), CHA group (P<0.01) and blank group (P<0.001) (Fig. 4D and E). New bone could also be found in rDFCs/CHA, and was obviously more than in CHA group and blank group compared to CHA group and blank group (P<0.01) (Fig. 4D and E). Those results suggested that BMP9-rDFCs/CHA implantation could significantly promote alveolar bone regeneration.
BMP proteins could act through Smad dependent or Smad independent manner. To investigate the roles of Smad pathway played in BMP9 induced rDFCs osteogenic differentiation, we first analyzed the Smad1/5/8 protein phosphorylation in those cell population. The results showed that Smad1/5/8 protein was induced in all groups and level of phosphorylated Smad1/5/8 protein (p-Smad1/5/8) was only significantly increased in Ad-BMP9-transfected rDFCs (Fig. 5A and Supplementary Fig. S1). We also applied the Smad1/5/8 pathway inhibitor (Compound C, Com C) into the cells culture.ALP activity, ALP staining, and Alizarin red staining results of showed that the osteogenic differentiation was attenuated by Com C in a dose-dependent manner (Fig. 5B,C and D). At the concentration of 500nmol/L, the inhibitor achieved the maximal osteogenic inhibition effects. Meanwhile, we have verified the expression of osteogenic markers. The Real Time-qPCR results showed that the mRNA level of ALP, Osterix, and OPN were remarkably reduced by adding Smad1/5/8 pathway inhibitor (Fig. 5E,F,G and H). These findings indicated that Smad1/5/8 signaling pathway might be involved in BMP9-induce osteogenesis of rDFCs.
The three key elements of tissue engineering study are cells, growth factors and scaffolds. In this report, we demonstrated that rDFCs could thrive on the CHA scaffold and BMP9 could strongly promote the osteogenesis of rDFCs. Based on these findings, we architected a novel implant composed of Ad-BMP9-transfected rDFCs and CHA. This novel implant has been tested in vivo on a rat alveolar bone defect model. The results were very promising by showing the significant bone regeneration in the defected area. Our data also suggested that the Smad1/5/8 signaling pathway was involved in BMP9 promoted rDFCs osteogenic differentiation.
As one of the multipotent cells, rDFCs derive from ecto-mesenchymal tissue have the capacity to differentiate into osteoblasts and the potential for alveolar bone regeneration38–40. Our results demonstrated that rDFCs treated with Ad-BMP9 had strong ALP activity and mineralize deposition. Furthermore, Real Time-qPCR analysis of osteogenic marker genes including: ALP, Osterix, OPN, was significantly induced by BMP9 in vitro. These results indicated that BMP9 could promote osteogenic differentiation of rDFCs.
CHA scaffolds could serve as a cell carrier to repair the bone defects in previous studies and clinical cases31, 41. Due to the excellent shape and mechanical properties41–43, in this study, SEM data showed rDFCs could adhere to and then proliferated on the CHA. And the expression levels of OPN, ALP and Osterix were enhanced by CHA. This result indicated that CHA could also facilitate the osteogenic differentiation of rDFCs in vitro 22, 24, 44, 45. The diameter of CHA pores was ranging from 100 to 600 μm similar to the structure of cancellous, which was beneficial for cell-growth and vascularization in the formation stage of new bone44, 46, 47. The formation of a little new alveolar bone, due to the osteoblasts derived from the adjacent bone marrow cavities48, was found in CHA treatment group. This indicated that it did not achieve enough bone formation to repair alveolar bone defect in clinical by CHA scaffolds only. The combined CHA and rDFCs improved bone regeneration and mineralization compared to CHA alone according to the results of histological analysis and Micro CT study. And this effect might be related to the implanted rDFCs. The osteogenic activity of rDFCs might contribute to stimulate the resident osteoblasts and promote more new bone formation. However, the new bone was still limited to meet the alveolar bone defect.
To enhance more new bone formation, Ad-BMP9-transfected rDFCs combining with CHA were used. Some researchers reported that BMP9 had more potent in inducing osteogenesis of stem cells compared to other BMP family members16, 46. Recently, some successful researches in vitro and vivo suggested that the application of BMP9 could prove to be a useful approach to promote bone regeneration11, 17, 37, 47. In our study, immature fibrous-like bone with macrophagocytes and plenty of blood vessels were found in rDFCs/CHA group and BMP9-rDFCs/CHA group in immunodeficient mice. It cleared that the application of rDFCs could prove to be a useful approach to promote new bone regeneration. And our study also determined that whether the new combination therapy of BMP9-transfected rDFCs and CHA is possible for periodontal alveolar bone tissue engineering and for future clinical use. Histological studies in this study showed that the combination of BMP9-transfected rDFCs and CHA could significantly enhance the osteogenic differentiation of rDFCs and promote the osteogenic activity and alveolar bone regeneration. The Micro CT data verified this result and showed more new bone in BMP9/rDFCs/CHA group than other groups. BMP9 mediated the osteogenic activity of rDFCs and resident osteoblasts, and then promoted new bone formation. And the novel compound implants of Ad-BMP9-transfected rDFCs and CHA had the best effect in repairing the alveolar bone defect of rat. The tissue-engineered technique combined with BMP9, rDFCs and CHA achieved the best effects in repairing the alveolar bone defect of rat. However, there are many problems before clinical use, such as the security of this new bio-implant, the long-term effectiveness and the evaluation of this method.
BMP receptors and phosphorylated of Smad1/5/8 proteins are essential signaling mediators for BMP signaling pathway19, 45, 49, 50. The binding of BMP type I and type II receptors could introduce the phosphorylation of Smad1/5/8.Then, the phosphorylated Smad1/5/8 forms a heterodimeric complex with Smad4, which activates the transcription of target genes in the nucleus45. Compound C, a BMPs inhibitor, can block the BMP type I receptors (ALK1, ALK2, and ALK6) disrupting the phosphorylation of Smad1/5/8, without affecting MAPK activation24. In this study, our results revealed that the phosphorylated Smad1/5/8 proteins were significantly increased in BMP9 transfected rDFCs. It suggested that BMP9 could act through Smad1/5/8 signaling pathway in rDFCs osteogenesis. This hypothesis was further emphasized by finding that Compound C inhibited the osteogenic differentiation of BMP9-induced rDFCs. Thus, we suggested the activation of Smad1/5/8 signaling is required in BMP9-induced osteogenesis of rDFCs.
In conclusion, we have assembled a new type of implant with Ad-BMP9-transfected rDFCs and CHA. The BMP9 could boost the rDFCs osteogenic differentiation on the bio-degradable CHA scaffold through Smad signaling pathway. With this novel implants, the tissue-engineered technique combined with Ad-BMP9-transfected rDFCs and CHA achieved the best effects in new alveolar bone formation. These findings might lead to a novel approach in treating periodontitis related alveolar bone defects.
The consent procedure and experimental protocol were provided by laboratory of oral biomedical engineering of higher education of Chongqing Medical University (License: SCXK[YU]2012–0001). The experiments in the study were approved by the Ethics Committee of Chongqing Medical University. The procedures in the present study were in accordance with the National Institute of Health guidelines on the ethical use of animals51.
Primary rDFCs were prepared and cultured as previously described11. Briefly, dental follicles were removed carefully from dental germs of neonatal rats’ mandibles. These cells were maintained in complete medium (DEME/F12, 10%FBS, 100μg/mL streptomycin and 100U/mL penicillin) and incubated at 37°C in a humidified environment of 5% CO2. At the 3rd passage, cells were re-suspended for further experiments. All animals were purchased from the Experimental Animal Center of Chongqing Medical University (License No: SCXK [Yu] 20012–0001).
80% confluence cells (passage 3) were digested by 0.25% trypsin, re-suspended and re-cultured in a humidified environment of 5% CO2 for 3hours. Then, transfection was done with Ad-BMP9 at an appropriate MOI (multiplicity of infection, MOI, efficiency about 70%) followed by refreshing the basal medium in 4hours. Adenovirus only expressing green fluorescence (Ad-GFP) was used as negative control. In blank experiment, polybrene (1μM/mL) was only added52, 53. Cells were observed after 24 or 48hours culture under the fluorescent microscope for quality control. Ad-BMP9 and Ad-GFP were provided by Dr. TC He (University of Chicago Medical Centre, USA).
ALP activity was detected by chemiluminescence assay (alkaline phosphatase activity kit, Beyotime, China) and histochemistry staining (ALP staining Beyotime, China) as previously described11. Each assay condition was performed in triplicate and the results were determined by three independent experiments.
Calcium deposition was stained with Alizarin Red S (Solarbio, Beijing, China), as previously described11. The cells were washed by PBS twice and incubated in 4% paraformaldehyde at room temperature for 30minutes. After washed by double distilled water, the fixed cells were stained with 2% Alizarin Red Sat 37°C for 20minutes, followed by extensive washing by double distilled water. The staining results were recorded by an inverted microscope.
The total mRNA was extracted by using RNA Extraction Kit (TaKaRa, Japan) on days 3, 5, 7, 9. cDNA was prepared by PrimeScriptTM RT reagent Kit (TaKaRa, Japan) according to the manufacturer’s instructions. Real Time-qPCR was employed to quantify the osteogenic gene expression (runt-related transcription factor 2, Runx2, alkaline phosphatase, ALP, osteopontin, OPN, Osterix) by using the SYBR green detection method as previously described54. All samples were run in triplicate and normalized by the expression of β-actin55. And the primers were synthesized by Genscript (Nanjing, China). The detailed primer information was as followed:
ALP, F: 5′-CCTGCAGGATCGGAACGTCAATTA-3′, R: 5′-TGAGTTGGTAAGG-CAGGGTCC-3′. OPN, F: 5′-CCAGCCAAGGACCAACTACA-3′, R: 5′-AGTGTT-TGCTGTAATGCGCC-3′. Runx2, F: 5′-CCGAGACCAACCGAGTCATTTA-3′, R: 5′-CCGAGACCAACCGAGTCATTTA-3′, Osterix, F: 5′-GCCAGTAATCTTCGTG-CCAG-3′, R: 5′-TAGTGAGCTTCTTCCTGGGGA-3′. β-actin, F: 5′-CCCGCGAG- TACAACCTTCTTG-3′,R: 5′-GTCATCCATGGCGAACTGGTG-3′.
80% confluence cells were lifted in 0.25% tryptin,and re-suspended at a density of 2×106 cells/ml onto CHA scaffolds (coralline hydroxyapatite, CHA, TBGC, China), which has been soaked in DMED medium containing 10% FBS for 2hours. The cell-CHA combination was then cultured in a humidified environment with 5% CO2 at 37°C. The medium was refreshed in every 3 days. The compound morphology of rDFCs and CHA (3 samples every day) was observed by SEM days 1 to days 7. At defined time points, the samples were rinsed twice in PBS and fixed in 2% glutaraldehyde for 2hours before further preparation for SEM observation. Then, the scaffolds were washed by 0.1mol/L solium-cacodylate for 30minutes, dehydrated in a series of ethyl alcohol (50–100%) before being dried for SEM.
In order to investigate the osteogenesis of the new implantation (the compound of BMP9, rDFCs and CHA) without any stimulation, the ectopic bone formation experiments were done as follow: Total five immunodeficient mice were used in the ectopic implantation experiments. The transplants were prepared by culturing Ad-BMP9 transfected rDFCs on CHA for 7 days as previously described56. The immunodeficient mouse was anaesthetized by intraperitoneal injection of 1% pentobarbital (Nembutal 3.5mg/100g body weight). Four skin incisions about 1cm in length were made on the dorsal surface of each mouse and implants (5samples each group) were placed into the pockets formed by blunt dissection. Then incisions were later closed by interrupted sutures. All mice were sacrificed after 6 weeks. The samples were immediately fixed in 4% paraformaldehyde (PH 7.4) for 48hours at 4°C followed by decalcification (15% EDTA -2Na solution, PH 7.4) and gradual dehydration before being embedded in paraffin wax. 5 μm thick sections were made and then stained with hematoxylin and eosin.
In order to test whether the novel implantation (the compound of BMP9, rDFCs and CHA) would support bone formation to restore alveolar bone defect in an acute traumatic inflammatory environment, the alveolar bone defect animal experiments were done as follow: Twenty SD rats were randomly divided into four groups in the alveolar bone regeneration experiments. The blank group received no implants. The CHA group was given CHA scaffolds only. The rDFCs/CHA group got 7-day-co-cultured rDFCs-CHA scaffolds. And the BMP9-rDFCs/CHA group acquired 7-day-co-cultured Ad-BMP9-transfected rDFCs-CHA scaffolds. For each experiment, rats were anaesthetized by intraperitoneal injection of 1% pentobarbital (Nembutal 3.5mg/100g body weight). The periapical alveolar bone of first and second molars was exposed by surgical means and an osseous defect (5*2*2mm3) was created by round dental bur as previously described54, 56, 57. The defected area was then filled up with or without implants accordingly and covered by a collagen membrane (7*5mm2). After that, the wound was closed with interrupted sutures. All animals were sacrificed 6 weeks after surgery. The alveolar bones were extracted and fixed in 4% paraformaldehyde (PH 7.4) for 48hours at room temperature before Micro CT analysis or hematoxylin and eosin staining. To calculate the percentage of new bone formation over total defect for each group, at least 20 random high-power field of cross sections per group were evaluated by a picture-analysis system (the Image-Pro Plus software).The Micro-CT settings were as follows: pixel matrix, 2048×2048; Slice thickness, 10µm; FOV/Diameter, 21.5mm; Energy/intensity, 70 KVp, 114µA, 8W. 3D images were reconstructed by µCT-6.1 software (Scanco Vival CT 40, Switzerland)57, 58. Briefly, the threshold (205 to 500, represent gray value of new mineralization tissue) of gray value was selected. Another threshold (500 to 550) of gray value was regarded as old alveolar bone tissues. The values above 550 and below 205 were separately regarded as scaffold materials and void or soft tissues. Where scaffolds were was in red in 3D reconstruction images. The volume of interest (VOI) was a 5mm3 cubic volume selected at the central defects in the threshold (205 to 500) from 3D images (n=5), and the VOI was used to access the new bone formation.
Cells were collected and lysed as previous described22. Rabbit anti-rat Smad1/5/8 (1:500) (Santa Cruz, USA), Rabbit anti-rat p-Smad1/5/8 (1:200) (CST, USA), Anti-β-actin antibody (1:1000) (Cell Signaling Technology, USA), were incubated with PVDF membrane respectively overnight at 4°C, followed by the incubation with secondary antibody Goat anti-rabbit (1:3000) (Sino Biological, Beyotime, Shanghai, China). The ECL Chemiluminescent Substrate Kit was utilized to detect the target proteins. All experiments were carried out in triplicate.
Re-suspended cells were incubated and tansfection was done with Ad-BMP9 or Ad-GFP at an appropriate MOI (transfection efficiency about 70%) followed by supplement with different concentration of Compound C (0nM, 50nM, 100nM, 500nM). ALP activity was assayed by chemiluminescence assay (alkaline phosphatase activity kit, Beyotime, China) and histochemistry staining assay (ALP staining Beyotime, China) as previously described on day 7. And the detection of calcium deposition was done by Alizarin Red S. The osteogenic genes were detected by Real Time-qPCR. Each assay condition was performed in triplicate and the results were determined by three independent experiments.
All experiments in our present study were repeated three times. The values in this study were shown as means±standard deviation (S.D.). Differences were analyzed by student’s t-test or one-way analysis of variance (ANOVA) in SPSS (SPSS 19.0). P<0.05 was considered as statistically significant.
The procedures in the present study were in accordance with the National Institute of Health guidelines on the ethical use of animals. The experiments in the study were approved by the Ethics Committee of Chongqing Medical University and the experimenter had also got the license of animal experiments (License No: CQLA-2014–0678). All animals were purchased from the Experimental Animal Center of Chongqing Medical University (License No: SCXK [Yu] 20012–0001).
We thanked Dr. T.C. He (University of Chicago Medical Centre, USA) for providing the Ad-BMP9 and Ad-GFP. This work was supported by the Nature Science foundation of Chongqing (cstc2015jcyjA0045, cstc2016jcyjA0045 and cstc2014jcyjA10055) and Chongqing municipal health and family planning commission (2016MSXM049).
C.L. initiated the project; C.L. and L.N. designed the experiments and wrote the manuscript; L.N., X.Y., L.D., E.H., P.Z., W.L., Y.Z., X.Z., Y.Q., T.C. performed the experiments; C.L. monitored the experiment sand revised the manuscript. All authors approved the final manuscript.
The authors declare that they have no competing interests.
Li Nie and Xia Yang contributed equally to this work.
Electronic supplementary material
Supplementary information accompanies this paper at doi:10.1038/s41598-017-06548-7
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.